New Study published showing Nevisense impact on clinician confidence and accuracy
STOCKHOLM, SWEDEN, — January 26, 2022 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study supporting the use of Nevisense in diagnosing melanoma has been published in "SKIN – The journal of cutaneous medicine". The article is authored by Avani Kolla, Prof David Polsky and others from The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine in New York. The study shows that Nevisense provides valuable diagnostic guidance when evaluating atypical pigmented skin